CSTF2 and glioma: Results of the overall survival curve (Figure 7B) and progression-free survival curve (Figure 7C) showed that CSTF2 had a considerable impact on the prognosis of patients with kidney cancer, glioma, liver cancer, pancreatic cancer, melanoma, and other cancer types (p-values < 0.01).